Mode
Text Size
Log in / Sign up

TAVR associated with higher 10-year mortality compared to surgery in intermediate-risk aortic stenosisTrial shows surgery may offer better long term survival for aortic stenosis

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that TAVR is associated with higher 10-year mortality and reintervention rates compared to surgery in intermediate-risk patients.

This randomized trial evaluated the long-term outcomes of transcatheter aortic valve replacement (TAVR) compared to surgical intervention in a population of patients with severe, symptomatic aortic stenosis at intermediate surgical risk. The study enrolled 1,910 patients across 57 centers, with 974 patients undergoing TAVR using the balloon-expandable SAPIEN XT system and 936 patients undergoing surgery.

The primary outcome measure was all-cause mortality over a follow-up period of 10 years. The results indicated a statistically significant difference in overall survival between the two groups. Specifically, the all-cause 10-year mortality rate was 86.1% for the TAVR group compared to 82.8% for the surgery group (HR: 1.13; 95% CI: 1.02-1.25; P = 0.02). This indicates a higher mortality rate in the TAVR cohort.

Subgroup analyses by access site provided further detail on these results. In the transfemoral (TF) access group, all-cause mortality was 83.9% for TAVR versus 82.1% for surgery (P = 0.27), showing no significant difference. However, in the transapical/transosteal (TA/TAo) access group, mortality was significantly higher in the TAVR cohort at 93.2% compared to 85.1% for surgery (P < 0.01; P for interaction = 0.03). These findings suggest that the choice of access may influence long-term outcomes.

Secondary outcomes included aortic valve reintervention and mean gradients at 10 years. The rate of aortic valve reintervention was significantly higher in the TAVR group (6.3%) compared to the surgery group (1.6%) with a p-value of less than 0.001. Mean gradients remained comparable between the two groups at 10 years, recorded at 12.6 mm Hg for TAVR and 12.7 mm Hg for surgery.

Regarding safety and tolerability, specific adverse event rates or discontinuation figures were not reported. However, the study noted that differences in mortality were predominantly observed in the TA/TAo access cohort. A significant limitation of the study was the small sample size available for long-term assessment; only 24 TAVR and 35 surgical patients had echocardiographic data available at the 10-year mark.

These results contrast with previous findings suggesting comparable mortality between TAVR and surgery in severe symptomatic aortic stenosis. The current trial highlights a specific risk associated with certain access routes in intermediate-risk patients. Clinicians should consider these findings when selecting an intervention for intermediate-risk patients, particularly noting the higher reintervention rates and the impact of access site on survival. Questions remain regarding the specific clinical factors that drive the increased mortality in the TA/TAo cohort and whether different TAVR systems or improved techniques might mitigate the observed differences in reintervention rates. The limited number of patients with 10-year echocardiographic data also leaves some questions regarding long-term structural performance.

How this fits prior evidence

How this fits prior evidence This finding contrasts with previous reports indicating that TAVR shows comparable mortality to surgery in severe symptomatic aortic stenosis. While those earlier findings suggested similar survival, the current trial identifies a higher 10-year mortality rate for TAVR (86.1%) compared to surgery (82.8%) in intermediate-risk patients, specifically highlighting a significant difference in the TA/TAo access group. Additionally, this study confirms that TAVR may involve higher risks of reintervention than surgery.

People living with severe, symptomatic aortic stenosis face a serious heart condition where the aortic valve becomes narrow and stiff. This makes it harder for blood to flow from the heart to the rest of the body. Patients with this condition often need treatment to improve their quality of life and manage their symptoms. For many years, doctors have used two main methods to treat this: traditional open-heart surgery or a less invasive procedure called TAVR (transcatheter aortic valve replacement). This study looks at which of these two options provides better long term results for patients who are at an intermediate risk for surgery.

To find the answer, researchers conducted a large randomized trial involving 1,910 patients across 57 different centers. The participants were divided into two groups: one group received the TAVR procedure using a specific balloon-expandable system, and the other group underwent traditional surgery. Because of the large size of the study and the long follow up period of 10 years, it provided a significant amount of data regarding how these treatments perform over a decade rather than just a few months.

The results showed that patients who underwent surgery had a lower rate of all-cause mortality compared to those who received TAVR. Specifically, the mortality rate was about 82.8 percent for the surgery group versus 86.1 percent for the TAVR group. The study also found that patients who received TAVR were more likely to need another procedure on their heart valve within 10 years compared to those who had surgery. However, the researchers noted that these differences in survival were most noticeable in a specific group of TAVR patients who had their procedure through certain access points.

It is important to note some limitations in this data. Only a small number of patients in both groups had available heart scans at the 10-year mark, which means the researchers could not compare the physical condition of the valves as clearly as they might have liked. Additionally, while the study shows a link between the type of procedure and survival rates, it does not mean that TAVR is inherently unsafe or ineffective for everyone. For patients today, this means that the choice between surgery and TAVR involves many factors. While TAVR is often less invasive in the short term, this study suggests that surgery may offer more durable results over a 10-year period for certain types of patients. Patients should talk to their heart specialists to discuss their specific risk factors and determine which treatment path offers the best long-term outlook for their individual health needs.

What this means for you:
A 10-year study suggests surgery may offer better survival rates than TAVR for some aortic stenosis patients.

Study Details

Study typeRct
Sample sizen = 2,013
EvidenceLevel 2
Follow-up120.0 mo
PublishedJun 2026
View Original Abstract ↓
BACKGROUND: Transcatheter aortic valve replacement (TAVR) is an established alternative to surgical aortic valve replacement for symptomatic severe aortic stenosis, but long-term, comparative clinical outcomes and echocardiography data are lacking. OBJECTIVES: Our goal was to compare 10-year clinical and echocardiographic outcomes after balloon-expandable TAVR or surgery in intermediate-risk surgical patients in the PARTNER 2A randomized trial. METHODS: Between 2011 and 2013, patients with severe, symptomatic aortic stenosis at intermediate surgical risk were randomized at 57 centers to TAVR with the balloon-expandable SAPIEN XT system (Edwards Lifesciences) or to surgery. Randomization was stratified by anatomical suitability for transfemoral (TF) or transthoracic (transapical/transaortic [TA/TAo]) access. Ten-year outcomes were evaluated in the valve implant population and included all-cause mortality, aortic valve reintervention, and core laboratory-adjudicated echocardiographic outcomes. To obtain 10-year data, patient reconsent at 5 years was required, and vital status sweeps were implemented to improve data completeness for all-cause mortality. RESULTS: Among 1,910 randomized patients who received a valve, 974 underwent TAVR (TF: 749/974 [76.9%]) and 936 had surgery. Mean patient age was 81.6 years, 45.4% were women, and the mean Society of Thoracic Surgeons score was 5.8%. At 10 years, vital status was available for 881 of 974 patients (90.5%) and 838 of 936 patients (89.5%). All-cause 10-year mortality with vital status sweeps was 86.1% after TAVR and 82.8% after surgery (HR: 1.13; 95% CI: 1.02-1.25; P = 0.02). When stratified by access route, rates of all-cause mortality for TAVR and surgery in the TF group were similar (83.9% vs 82.1%, respectively; P = 0.27), whereas mortality was higher for TAVR in the TA/TAo group (93.2% vs 85.1%; P < 0.01; P for interaction = 0.03). Cumulative incidence rates of aortic valve reintervention at 10 years were 6.3% for TAVR and 1.6% for surgery (P < 0.001). Of the 24 TAVR and 35 surgical patients with available echocardiographic data at 10 years, mean gradients were 12.6 mm Hg and 12.7 mm Hg, respectively. CONCLUSIONS: At the 10-year follow-up, TAVR in intermediate-risk patients with the SAPIEN XT prosthesis compared with surgery was associated with lower survival rates, with differences predominantly observed in the TA/TAo access cohort. TAVR with the XT valve was also associated with significantly higher rates of aortic valve reintervention. (PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - XT Intermediate and High Risk [PII A]; NCT01314313).
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.